Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2010 Oct;7(10):561-74. doi: 10.1038/nrclinonc.2010.122. Epub 2010 Aug 31.

Rechallenging with anthracyclines and taxanes in metastatic breast cancer.

Author information

1
Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK. c.palmieri@imperial.ac.uk

Abstract

Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse following adjuvant therapy, and whether there is a role for rechallenging in the metastatic setting with the same agent, or class of agent, that has been utilized in the adjuvant setting. This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials.

PMID:
20808300
DOI:
10.1038/nrclinonc.2010.122
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center